Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognosis of Lipid Reprogramming With the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

NCT04776889 is registered in ClinicalTrials.gov with National Cancer Institute, Egypt as lead sponsor.

NCT NCT04776889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognosis of Lipid Reprogramming With the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients
Lead sponsor
National Cancer Institute, Egypt
Phase
Phase 4
Overall status
Completed
Start date
January 15, 2019
Completion date
December 30, 2020
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic